跳至主要内容
临床试验/ISRCTN62125126
ISRCTN62125126已完成未知

A pharmacokinetic investigation into the formation of carbamazepine metabolites and carbamazepine-protein conjugates in epilepsy patients

niversity of Liverpool0 个研究点目标入组 158 人开始时间: 2015年2月19日最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
158

研究概览

简要总结

2021 Results article in https://pubmed.ncbi.nlm.nih.gov/33217013/ (added 21/09/2021)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • Autoinduction group:
  • 1. Subject is willing and able to give written informed consent
  • 2. Subject is aged 18 or over
  • 3.Subject is newly prescribed carbamazepine by their attending physician
  • Maintenance group:
  • 1. Subject is willing and able to give written informed consent
  • 2. Subject is aged 18 or over
  • 3. Subject has received CBZ therapy at the same dosage for at least 4 weeks

排除标准

  • Autoinduction group:
  • 1. Subject is not willing to take part or unable to give written informed consent
  • 2. Subject has in the past 4 weeks received other medication that is a CYP3A4 inducer or inhibitor (see medications below)
  • 3. Subject has taken part on another research study within 90 days of commencement
  • 4. Subject has any condition which in the opinion of the investigator will interfere with the study
  • Excluded medications:
  • Rifampicin, Amiodarone, Fluvoxamine, Saquinavir, Rifampin, Amprenavir, Indinavir, SVerapamil, Isoniazid, Atazanavir, Lopinavir, Verapamil, Phenytoin, Azithromycin, Mifepristone, Phenobarbital, Grapefruit juice, Nelfinavir, Omeprazole, Clarithromycin, Norverapamil, Clotrimazole, Cyclosporine A, Ritonavir, HMGCoA reductase inhibitors, Delavirdine, Ndesmethylerythromycin, Cyclophosphamide, Erythromycin, Roxithromycin, Spironolactone, Fluoxetine, RVerapamil
  • Maintenance group:
  • 1. Subject is not willing to take part or unable to give written informed consent
  • 2. Subject has any condition which in the opinion of the investigator will interfere with the study

研究者

发起方
niversity of Liverpool

相似试验